A mid-stage trial of 4D Molecular Therapeutics gene therapy for eye disease age-related macular degeneration (AMD) 4D-150 has shown promising signs of efficacy, plus a red
Eli Lilly’s acquisition of gene therapy specialist Akouos seems to have paid off, after the lead candidate in the deal restored hearing in a child with congenital deafness
